

# Considerations When Using a Potassium Binder in Patients with CKD

## References

### MECHANISM OF ACTION

1. Palmer BF. Regulation of Potassium Homeostasis. *Clin J Am Soc Nephrol*. 2015;10(6):1050-1060. doi:10.2215/CJN.08580813
2. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. *Am J Manag Care*. 2015;21(11 Suppl):S212-S220.
3. Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
4. Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical Management of Hyperkalemia. *Mayo Clin Proc*. 2021;96(3):744-762.
5. Lesko LJ, Offman E, Brew CT, et al. Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. *J Cardiovasc Pharmacol Ther*. 2017;22(5):434-446. doi:10.1177/1074248417691135 *Cochrane Database Syst Rev*. 2020;6(6):CD013165. Published 2020 Jun 26.
6. Li L, Harrison SD, Cope MJ, et al. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia. *J Cardiovasc Pharmacol Ther*. 2016;21(5):456-465.
7. Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. *Eur J Heart Fail*. 2015;17(10):1057-1065.
8. Veltassa [package insert]. Redwood City, CA: Vifor Pharma, Inc. December 2021
9. Zannad F, Hsu BG, Maeda Y, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. *ESC Heart Fail*. 2020;7(1):54-64.
10. Lokelma [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021

### PRESENTERS' SLIDES

1. Remuzzi G, et al. *J Clin Invest*. 2006;116(2):288-296.
2. SOLVD Investigators, et al. *N Engl J Med*. 1991;325(5):293-302. CONSENSUS Trial Study Group. *N Engl J Med*. 1987;316(23):1429-1435. Zannad F, et al. *N Engl J Med*. 2011;364(1):11-21. Pitt B, et al. *N Engl J Med*. 1999;341(10):709-717. McMurray JJ, et al. *Lancet*. 2003;362(9386):767-771. McMurray JJV, et al. *N Engl J Med*. 2014;371(11):993-1004.
3. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. *Kidney Int*. 2012;82(3):330-337. doi:10.1038/ki.2012.74
4. Weir MR, et al. *N Engl J Med*. 2015;372(3):211-221.
5. Bakris GL, et al. *JAMA*. 2015;314(2):151-161.
6. Rossignol P, et al. *Eur J Heart Fail*. 2020;22(8):1378-1389.
7. Kosiborod M, et al. *JAMA*. 2014;312(21):2223-2233.